Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.036 -5.07% 0.674 27,540,318 16:35:26
Bid Price Offer Price High Price Low Price Open Price
0.674 0.69 0.705 0.682 0.705
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.03 -7.66 -0.60 47
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:26 UT 51,470 0.674 GBX

Tissue Regenix (TRX) Latest News

More Tissue Regenix News
Tissue Regenix Investors    Tissue Regenix Takeover Rumours

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix Forums and Chat

Date Time Title Posts
05/3/202112:23Tissue Regenix delivering practical solutions to real clinical issues6,389
26/5/202012:31Torex with Charts & News14
15/1/202007:09TOREX 2007 - THE TILLS RING AT LAST13
14/1/202020:51Terrane Minerals- Cu explorer, trading in Canada17
12/11/201915:05Fair Value ?4

Add a New Thread

Tissue Regenix (TRX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Tissue Regenix trades in real-time

Tissue Regenix (TRX) Top Chat Posts

Tissue Regenix Daily Update: Tissue Regenix Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 0.71p.
Tissue Regenix Group Plc has a 4 week average price of 0.64p and a 12 week average price of 0.43p.
The 1 year high share price is 1.28p while the 1 year low share price is currently 0.28p.
There are currently 7,033,077,499 shares in issue and the average daily traded volume is 37,744,318 shares. The market capitalisation of Tissue Regenix Group Plc is £47,402,942.34.
carlisle44: Cyberbub I think the company has done well in the past 8 or so months. The fundraise felt like a shotgun rush and came hot on the heels of two US Gov grants to assist TRX. My holding was decimated as a consequence of the draconian discount and share increase (sevenfold or so), and while one might say that the Primary Bid raise was open to all , it was; but only if, one responded within the few hours allocated for uptake! A higher offer price should have been sought in my view. You may recall that the capital raise was oversubscribed. We are where we are and good to see TRX heading North at a good rate. GL to all long term holders.
emeraldzebra: Bit odd that the last trade seems to have been at 0.79p (up about 10 per cent) - yet the 'close' value was up only up 3.8 per cent ? Anyone know the share price on the 77m trade please ?
lazygun: Gareth Jones did a great job in overseeing that massively diluted fund raise last year. Trx are doing better than I expected in starting to recover from that debacle. It’s entirely possible if they are starting to see continued upticks in business this year, for them to double from here. Was reading back their trading update, and overall seems quite positive. Demand seems to be there for their products, with covid being the main factor in holding them back. Assuming the vaccination programs globally demonstrate their effectiveness, we may see a faster recover in tissue’s share price than I had previously expected. Think they also need to do a share consolidation - 7 billion shares is too many.... L.
channel pirate: If TRX is managed correctly, assuming there is no "take out", then the potential is massive. Certainly a Global awareness in the waiting. However, one of the bigger global medical "big boys" will be keeping an eye on us and probably 'pounce' when the time is right. Like to see our share price in double figures at least before that happened though. Just hope it happens before I pop my clogs, and I get some time to enjoy the rewards - the kids can wait a bit longer for their inheritance !!
hodhasharon: Employee Share Scheme 0.2% 16,106,800 shares Private Companies 0.7% 51,631,915 shares Public Companies 2.6% 184,212,642 shares VC/PE Firms 13.6% 953,042,837 shares Individual Insiders 14.1% 987,152,980 shares General Public 15.7% 1,101,368,488 shares Institutions 53.1% 3,723,449,037 shares
cerrito: For me a good Reassuring update but am not surprised at the share price Retreat this morning as the price action on Friday was rather premature. Good to see a company specifying their understanding of market expectations.
cerrito: The next RNS on the board composition will presumably be the announcement of the new FD following the departure of Gareth Jones.I assume he/she will be based in the UK rather than the US as TRX is listed. I note that the share price is riding high at a time when I assume elective procedures in hospitals in the US and UK and no doubt continental Europe are reduced.
thordon: Depends , some say that there is a code for sell or buy if remember if there are 1 share buy then followed later by 2 more 1 share buy then buy heavy as share price will rise. All hear say so please do not follow my advice
enteleon: Ali47fish- Consort Medical announced the Recipharm buyout on Monday, November 18th, 2019, so Glenn would have been very preoccupied exactly at the time of the worst shenanigans within the TRX Board associated with the MIDCAP debt deal. He was tied in with Consort until its last trading day, which was March 3rd, 2020. We outsiders cannot know the exact internecine squabbles within the Board. Perhaps the former Chairman, John Samuel, was awkward. Samuel had bought 2,000,000 shares at 10p sometime previously and we do not know if he is still a shareholder. Funding with debt is all about free cash flow. Some businesses like Vodafone have colossal debt, but very large FCF. TRX's sales figures show growth over several years and this is encouraging. Purely my conjecture that Glenn took a dim view of the MIDCAP interest rate terms at close to 10% p.a. and agitated to return the $5.5M as he was emerging from his Consort commitments. The asset value does count, of course, as this may be viewed as collateral. The Net Asset Value (NAV) of TRX maybe 6p per share (my guess and please correct me). We would all love to know if the Friday spike in share price is sustainable. The new tax-year starts Monday and there maybe some investors wanting to tuck shares into their ISAs. We are all having to live with so many uncertainties at micro and macro levels. If Glenn achieves funding without serious dilution, the share price will look very cheap, but it's a big IF !! There remain huge uncertainties about the course of the pandemic and this affects sentiment in general. I record the sad mortality figures for each major country on a daily basis. The USA, UK and France are still worsening. It appears that poor old Italy and Spain may be levelling out. Countries like Germany, the Netherlands and Austria (with very high testing rates) may be topping over the next few days. Global sentiment will be very much determined by the US experience. Governments will be very aware of the morbidities from the actual lockdown- economic, psychological and medical. Cancers don't stop growing; routine elective surgery postponed (very relevant to TRX), etc. My own view is that the medical field will remain in high profile and higher priority for some years to come. Sadly, there will be permanent destruction among airlines, cruise companies, high street retailers, some construction companies and some banks as we realign our global priorities. All this is purely my opinion; please DYOR; very best wishes to everybody; special thoughts to anybody on the front line, especially the valiant NHS staff who are real heroes.
enteleon: Chinadog3- Thank you for your compliment. I don't have any special(and certainly not insider) information about TRX. I have followed TRX for a while and nearly all my investments are in the medical/pharma/biotech space as these tend to be relatively defensive. I have a medical/surgical background. Ali47fish- I hope the below helps to put the Company circumstances into perspective. Please do correct me where necessary. TRX has been horribly hit by a combination of both Woodford and Invesco selling down in the second half of 2019. Woodford, as most of you know, was the former star of Invesco and Invesco tended to follow Woodford in the last few years. When things went badly wrong for Woodford, Invesco copied his selling. Additionally, TRX has been plagued by some very erratic management moves in the last 15 months, with several Finance Directors coming and going. The loan deal with MIDCAP was announced in November, 2019, but clearly met with major infighting within the Board. The then FD left almost immediately. The loan was at an interest rate of approx 6.7% plus LIBOR, which would have given a rate of close to 10% p.a. TRX borrowed approx $7.5M, but returned $5.5M in a major revision to the loan earlier this year. At present, I believe that TRX's total debt is $2M and this is to MIDCAP. The acquisitions that TRX has made in the past have been financed through share cash-calls, hence the large number of shares in issue (1,171,971,322). Woodford and Invesco were very supportive of these cash-calls. Returning the $5.5M to MIDCAP has left TRX with a cash-flow crisis with cash running out by the end of the second week in May. To address this, TRX has to raise debt, sell off the whole or part of the Company or hold a cash-call, the last of which would dilute all investors' holdings. Purely as my opinion, I do believe that the appointment of Jonathan Glenn to Chairman/CEO may be crucial. Glenn has been a non-exec director of TRX since Jan 2016. He made his name by steering Consort Medical (was CSRT) to a very successful buyout by the Swedish Recipharm Group, finalised in February this year at an enterprise value in excess of £500M. Glenn is a chartered accountant by profession, so is commercially savvy and knows TRX inside-out as well as having long experience in the medical appliance world (appointed CEO of Consort December, 2007). So, in summary, and this is purely my opinion: Erratic previous management, Woodford/Invesco divestment (there is still the 19.98% share overhang with Link) and perhaps some over-reach in acquisitions have left TRX asset-rich, but cash poor. Their products appear to be in considerable demand and have FDA approval- indeed one of the problems has been a supply-side crisis, not demand-side. TRX is now a commercial operation, not a research outfit. It needs serious commercial talent to pull the Company through what should be a short-term funding crisis. The Covid-19 pandemic has added additional stress, of course. To me, TRX is priced as if it was a small pharma/biotech company waiting for interminable FDA/CE approvals on a long-haul research basis. That is just not the case. Please, please correct and criticise; we are all here to learn. Wishing all long-holders the very best of luck.
Tissue Regenix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Tissue Reg..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210308 00:12:06